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Abstract
Background: Our earlier studies have shown that red blood cell (RBC) morphology in Alzheimer’s disease (AD)
subjects was altered (> 15% of the RBCs were elongated as compared to 5.9% in normal controls (p < 0.0001)). These
results suggested alterations in the RBC membrane architecture in AD subjects, possibly due to RBC-b-amyloid
interactions and/or changes in the expression of membrane proteins. We hypothesized that the observed changes
could be due to changes in the level of the protein components of the cytoskeleton and those linked to the RBC
membrane. To examine this, we performed a proteomic analysis of RBC membrane proteins of AD subjects, and their
age-matched controls using one pool of samples from each group, following their separation by SDS-PAGE, in-gel
Tryptic digestion, LC-MS-MS of peptides generated, and a label-free approach of semi-quantitative analysis of their
relative MS spectral intensities.
Results: The data suggest, (1) RBC shape/morphology changes in AD subjects are possibly attributed primarily to
the changes (elevation or decrease) in the level of a series of membrane/cytoskeleton proteins involved in
regulating the stability and elasticity of the RBC membrane, and (2) changes (elevation or decrease) in the level of
a second series of proteins in the RBC membrane proteome reflect similar changes reported earlier by various
investigators in AD or animal model of AD. Of particular interest, elevation of oxidative stress response proteins
such as heat shock 90 kDa protein 1 alpha in AD subjects has been confirmed by western blot analysis in the RBC
membrane proteome.
Conclusions: The results suggest that this study provides a potential link between the alterations in RBC
membrane proteome in AD subjects and AD pathology.
Background
Alzheimer’s disease (AD) is a progressive neurodegen-
erative disorder characterized by abnormal extracellular
deposition of b-amyloid (Ab) peptide and neuronal loss.
Recently, we have analyzed red blood cell (RBC) mor-
phology in blood from subjects with AD and reported
[1] that > 15% of the RBCs are elongated as compared
to 5.9% in normal controls (p < 0.0001). This observa-
tion suggests possible alterations in the RBC membrane
architecture in AD subjects. These changes are likely to
originate from modifications caused by Ab interactions
with RBCs [2,3] and/or changes in the expression level
of certain RBC proteins.
It is well established [4] that the cytoplasmic surface of
the RBC plasma membrane contains a two-dimensional
meshwork of proteins referred to as the spectrin mem-
brane cytoskeleton. Attached to integral membrane pro-
teins, this cytoskeleton provides elasticity, flexibility and
stability to the RBC, as the cells continuously flow
through the circulatory system. Passage through the nar-
row blood vessels and micro capillaries involve large
changes in shear stress and significant deformation of the
RBC. Because of the ease in obtaining RBCs and the lack
of internal RBC organelles, the plasma membrane of
these cells has been extensively studied. The identity,
* Correspondence: MohantyJ@mail.nih.gov
1National Institute on Aging, Baltimore, MD, USA
Mohanty et al. Proteome Science 2010, 8:11
http://www.proteomesci.com/content/8/1/11
© 2010 Mohanty et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.function, and topology of many RBC membrane proteins
have been determined [4-6]. A number of proteins asso-
ciated with the RBC cytoskeleton have been shown to
alter the shape of RBCs. Therefore, we hypothesized that
the observed increase in RBCs with a non-biconcave
shape from AD subjects [1], could be traced back to
changes in the level of the protein components of the
cytoskeleton and the proteins linking the cytoskeleton to
the membrane.
A recent review published by Goodman et. al.[ 7 ] ,
compiled the proteomic data on RBC proteins gathered
over the last five years by several laboratories. These
studies identified 751 proteins within the human ery-
throcyte, including about3 4 0m e m b r a n ep r o t e i n s
reported by Pasini et. al. in 2006 [8]. Many of the identi-
fied proteins were shown to play a role in regulating the
shape and stability of the RBC. Therefore, we performed
a proteomic analysis of RBC membrane proteins of AD
subjects, and their age-matched controls, to see if we
can explain the observed RBC shape changes in AD sub-
jects [1], and to determine whether RBC membrane pro-
teomics reflect changes in the level of proteins linked to
AD pathology.
Results and Discussion
LC-MS-MS data from RBC membrane proteins
As described in the Methods section below, membrane
proteins were prepared from two RBC pools (AD and
normal controls) consisting of 5 subjects in each pool.
Pooling samples shown by statistical analysis [9] to
d e c r e a s en o i s ea n d ,t h e r e b y ,i ncrease the reliability of
the determination, has been used in a proteomic analysis
of bronchoalveolar lavage proteins [10]. The membrane
proteins in control and Alzheimer pooled samples were
isolated using three different approaches: (1) membrane
preparation in pH 7.4 buffer followed by solubilization
with 2%SDS (Run 1); (2) membrane preparation in pH
8.0 buffer (pH 8 minimizes haemoglobin binding to the
membrane) followed by solubilization with 2%SDS (Run
2); and (3) membrane preparation in pH 7.4 buffer fol-
lowed by solubilization with SIGMA Protein Extraction
Reagent Type 4 (normally used for 2D electrophoresis,
Run 3). Each of these preparations of membrane pro-
teins was resolved through SDS-PAGE. After staining
and de-staining of the gels, sample lanes were sliced as
shown in Figure 1 (Run 1), and subjected to in-gel tryp-
sin digestion of proteins prior to elution of peptides for
analysis by LC-MS-MS. Thus, there were three sets of
data obtained from the analysis of proteins prepared by
three different approaches (Runs 1-3). By incorporating
three different methods of RBC membrane protein isola-
tion in this study, conclusions from RBC proteome ana-
lysis were believed to be independent of the methods
used.
Calculation of Spectral Intensity ratios from
LC-MS-MS data
We detected a total of 785 proteins in normal and AD
samples using LC-MS-MS data of three runs and their
analysis with Agilent’s Spectrum Mill software as
described in the methods. The autovalidation feature of
this software is unique and has been successfully used by
several investigators [11-13]. Some proteins were found
to be present in one, two or all three runs of both AD
and control samples, while some were found only in AD
or control samples. There were also significant differ-
ences in the levels of certain proteins for AD and control
samples. Several criteria were used to determine which
proteins displayed a significant increase or decrease in
their level in samples from AD subjects in comparison to
samples from normal control subjects. (1) Protein entries
with only one peptide match - considered insignificant -
were removed. This step removed 170 proteins, leaving
615 proteins for further consideration. (2) To make the
data more reliable, proteins with a unique score less than
25 were deleted. This step reduced the number of pro-
teins to 548. (3) Proteins detected only in one run - con-
sidered insignificant - were eliminated. This step reduced
the list of proteins to 224. (4) Among these 224 proteins,
three accession numbers had no specific protein name or
little available information - and so, were not considered
in the present study. (5) Among the rest of the 221 pro-
teins, there were two proteins observed only in AD sub-
jects, while 26 proteins were observed solely in normal
Figure 1 SDS-PAGE of RBC membrane proteins.S a m p l eo f
coomassie blue stained SDS-PAGE gel containing RBC membrane
proteins from AD (Alzheimer) subjects and age matched controls
(Normal) from Run 1. The numbers on right side of the gel indicate
slice numbers or the area where gel was cut. Numbers of left side
of the gel indicates molecular size (MW) in kilo Daltons (kDa).
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samples from AD subjects represent potential biomar-
kers. However, the identification of a biomarker would
require validation for the protein assignment and a
demonstration that the changes were present in a num-
ber of individual subjects. Such an analysis was beyond
the scope of this study and will be considered in a future
publication.
In this study, we focused our attention on the 193 pro-
teins detected in both AD and control samples.
Although, care was taken to minimize contamination of
platelets and nucleated cells during RBC isolation, minor
contamination may still be possible, which might contri-
bute to these 193 proteins. The mean intensities of these
proteins are compared for AD subjects and controls
using data from equivalent number of runs from
each group (Figure 2 scattered points). The line shown in
Figure 2 was generated for equivalent intensities in both
groups of subjects. Points to the right of the line indicate
proteins with elevated intensities in the AD subjects and
points to the left of the line indicate proteins with ele-
vated intensities in normal subjects. Figure 2 indicates
that there are a number of proteins with appreciable dif-
ferences in intensities when both groups are compared.
We focused our analysis on those proteins. To evaluate
significant changes between AD and normal subjects, the
total spectral intensities for each of the 193 proteins were
added separately and the ratios of the corresponding
total intensities (AD/normal) were calculated. Thus, for a
particular protein, a ratio value greater or lesser than 1
would indicate an increase or decrease respectively in its
level in the AD subjects. However, to make our data
more reliable, we considered a ratio of 1.5 or more
(1.5-fold or more increase) for a protein to be signifi-
cantly increased in AD subjects. Similarly, a ratio of 0.67
or lower (1.5-fold or more decrease) for a protein was
considered significant to conclude that the level of that
protein decreased in AD subjects. Thus proteins with a
ratio of greater than 0.67 and less than 1.5 were elimi-
nated from further consideration.
These above criteria reduced the number of proteins
being considered to 160. These proteins along with the
change in their respective level (AD/normal), their IPI
accession numbers, and their linked gene names are pre-
sented in a separate table as Supplementary material
(Additional file 1). Most of the proteins listed in this
table have been previously reported to be present in the
RBC proteome [7]. Proteins shown in bold were reported
to be present in the RBC membrane proteome by Pasini
et. al. [8], and proteins with asterisks have been reported
to be present in the whole RBC proteome by Goodman
et. al.[ 7 ] .T oa n a l y z ef u r t h e r ,w eh a v ef o c u s e do nt w o
groups of proteins, one that is involved with RBC cell
morphology and the other, which has been reported by
other investigators in AD as well as in animal models of
the disease.
Level of Membrane/Cytoskeleton proteins linked to RBC
morphology are altered in AD subjects
There is evidence for the formation of RBCs with
altered morphology in AD subjects [1,14,15], which
reflect perturbations impairing the required deformabil-
ity of the RBC. This deformability is accomplished by a
cytoskeleton on the cytoplasmic side of the RBC mem-
brane that consists of spectrin tetramers (2a and 2b
chains). The cytoskeleton is linked to the membrane by
a network of proteins that participate in both horizontal
and vertical interactions [16]. The spectrin hetero-dimer
is anchored to the plasma membrane via two vertical
attachment sites. The first attachment site is assembled
by the band 3-ankyrin complex that binds to a site near
the carboxyl terminus of b-spectrin, providing a
mechanism, by which the “head” region of the spectrin
hetero-dimer binds to the cytoplasmic surface of the
plasma membrane [16-18]. This linkage is strengthened
by the protein band 4.2. The second vertical bridge is
located at the “tail” region of the spectrin hetero-dimer
and is composed of several proteins collectively known
as the “junctional complex” [19,20]. This region of spec-
trin is associated with actin protofilaments, which are
bound to adducin and tropomyosin and linked to glyco-
phorin C via band 4.1 and dematin (band 4.9). Tropo-
modulin-1 is a well defined actin-capping protein that
Figure 2 Comparison of Mass Spectral intensities in normal
and AD samples. Comparison of the mean Mass-spectral intensities
of proteins (observed in two or three runs) in the RBC-membrane
proteome in normal and AD subjects. The line was generated for
equivalent intensities in both groups of subjects. Points to the right
of the line indicate proteins with elevated intensities in the AD
subjects and points to the left of the line indicate proteins with
elevated intensities in normal subjects.
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filaments [21]. This junctional complex has been shown
to play a critical role in the maintenance of erythrocyte
elasticity, shape and membrane stability [16,18,20].
Changes in the level of one or more of these proteins
may contribute to decreased deformability of RBC, lead-
ing to the decrease in blood flow through the microcir-
culation, impaired oxygen delivery and consequently to
AD pathology [1,22].
Our proteomic study of the RBC membrane in AD
subjects makes it possible to explain these morphology/
shape changes. In Table 1, we have listed the proteins
involved in the cytoskeleton network that are altered in
AD subjects relative to the normal controls. Our results
suggest that the level of band 4.2 protein increased by
70% in AD subjects. This increase may alter the proper
balance between band 4.2 and the link of the membrane
to the spectrin head. With respect to the junctional
complex involving the spectrin tail, there are significant
changes in the level of a number of proteins including
tropomodulin, tropomyosin, adducin, glycophorin,
dematin, and the F-actin capping protein. In addition,
we have also observed changes in the level of ezrin
which contains the N-terminal band 4.1 sequence
involved in binding to glycophorin. Interestingly, all of
the above stated proteins were implicated in changes in
RBC stability. However, the decrease in adducin and
dematin is of particular interest because of a study by
Chen et. al. [23], in which it has been shown that the
reduction in the level of either dematin or b-adducin
exerted modest effects on RBC shape and stability, with
a more pronounced effect when both proteins are
reduced/eliminated. These changes taken together sug-
gest altered morphology with decreased deformability
and stability of the RBCs in AD subjects.
Level of other Membrane/Cytoskeleton proteins linked to
Alzheimer’s disease are also altered in RBC of AD subjects
There is extensive literature describing changes in protein
levels associated with AD. Most of these studies are
focused on brain tissue in both human and animal models.
It is, possible to observe similar changes in RBC mem-
brane if the activation or inhibition of protein synthesis
observed in AD brains affect protein synthesis in other tis-
sues including RBCs. Alternatively, the observed changes
in RBC membrane from AD subjects may reflect proteins
that are taken up by RBCs when they come in contact
with these tissues [24-26]. For both of these reasons,
changes in RBC membrane proteins can be used to moni-
tor changes in AD pathology. Therefore, we searched the
literature to find if any of the proteins in our RBC mem-
brane proteome (Additional file 1) have any link to AD.
We looked for correlations with the reported change in
h u m a nA Ds u b j e c t so ri na na n i m a lm o d e lo fA D .P r o -
teins, showing similar changes in both our study as well as
in existing AD literature are listed in Table 2.
Adenylyl cyclase-associated protein, a transport/cytos-
keleton protein, was found to be 2.2 fold up-regulated in
presenilin knockout mice having neurodegeneration [27].
Oxidative stress has been implicated in AD and has been
reported to be elevated in presenilin knockout mice inde-
pendent of brain Ab deposition [28,29]. Aluminium-
induced oxidative stress in rat brain was shown to
increase the level of aminolevulinic acid dehydratase
(ALAD) in blood [30]. Hypoxia, known to cause oxidative
stress, was elevated in clinical AD [31], causing an
increase in stress response proteins such as heat shock 90
kDa protein 1 alpha (HSP90) [32,33]. For HSP90 we con-
firmed our MS data (Table 2) using western blot analysis
of RBC membrane proteins with a monoclonal HSP90
antibody, showing an elevation of HSP90 in four out of
five AD subjects (Figure 3). An increase in the oxidative
stress in AD is expected to result in an elevation [34,35]
of catalase in AD subjects as we noticed (Table 2). Aqua-
porin 1 (AQP1) expression in the cerebral cortex was
shown to have been increased at early stages of Alzhei-
mer disease [36]. Calgranulin B (S100A9), an inflamma-
tion-associated protein was reported to be expressed in
Table 1 Alteration in the level of RBC membrane/






IPI00028120 1.71 Erythrocyte membrane protein
band 4.2
IPI00220741 1.83 Spectrin alpha chain, erythrocyte
IPI00216704 2.07 Splice isoform 2 of P11277 Spectrin
beta chain, erythrocyte*
IPI00002375 2.88 Tropomodulin 1
IPI00218319 2.15 Splice isoform 2 of P06753
Tropomyosin alpha 3 chain
(tropomyosin 3 isoform 2)
IPI00220158 0.43 Splice isoform 3 of P35611 Alpha
adducin (Erythrocyte adducin
subunit alpha)*
IPI00026299 4.03 Splice isoform of P04921
Glycophorin C
IPI00216311 5.11 Villin 2 (cytovillin 2;, Ezrin) (has
high degree of similarity within its
N-terminal domain to the
erythrocyte cytoskeletal protein,
band 4.1, Gould et al., EMBO
Journal vol.8 no.13 pp.4133-4142,
1989)*
IPI00005969 7.84 F-actin capping protein alpha-1
subunit
IPI00292290 0.3 Splice isoform Long of Q08495
Dematin (Erythrocyte membrane
protein band 4.9)*
N.B. Proteins shown in bold letters have been reported by Pasini et. al. [8] to
be present in RBC membrane and those with asterisks have been reported by
Goodman et. al. [7] to be present in whole RBC proteome.
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Girardot et. al. [38], confocal microscopy evidence sug-
gests that flotillin-1 was accumulated most often in tan-
gle-bearing neurons in AD subjects. A report showed a
significant increase in specific activity of lactate dehydro-
genase A in frontal and temporal cortex of AD brains
[39]. Lactotransferrin expression was reported to be up-
regulated in both neurons and glia in affected AD tissue
[40]. It was reported that methylenetetrahydrofolate
dehydrogenase 1 (MTHFD1) genotype had a tendency of
increased frequency in AD subjects [41]. According to
Hye et al. [42], serum albumin precursor was elevated in
plasma from AD subjects and a similar elevation was
observed in brain of mouse model AD [43]. In contrast,
we have also observed two proteins - aldolase A and Ubi-
quitin-activating enzyme E1 - whose levels were
decreased in RBC proteome of AD subjects similar to
that reported in AD hippocampus proteome [44], and
AD brain samples respectively [45].
Conclusions
The present membrane proteomics data suggest two
aspects of how changes in the level of proteins in RBC
membrane can contribute to our understanding of AD. (1)
The shape/morphology changes observed earlier in the
RBC of AD subjects are most likely attributed primarily
to the changes in the level of a series of membrane/cytos-
keleton proteins that are involved in regulating the shape,
stability and elasticity of the RBC membrane. In turn,
these changes can alter RBC deformability and impair oxy-
gen transport in AD subjects. (2) The changes in the level
of a second series of proteins in our RBC membrane pro-
teome reflect similar changes reported earlier by other
investigators in AD subjects or animal models of AD. For
some of these proteins, such as HSP90 and L-lactate dehy-
drogenase A, the changes are very dramatic and may be
useful for AD diagnosis. We validated the increase of
HSP90 in the RBC membrane proteome from AD subjects
by using western blot analysis (Figure 3A &3B). Thus, this
study provides a potential link between the RBC mem-
brane proteome changes in AD subjects and AD pathol-
ogy. The potential significance of this study is indicated by
Table 2 Alteration in the level of RBC membrane/cytoskeletal proteins similar to those alterations in AD or its animal
model
Accession No. Fold Change (AD/Normal) Protein Name Citations showing Similar fold changes
IPI00008274 8.13 Adenylyl cyclase-associated protein [27]
IPI00010314 1.78 Aminolevulinate, delta-, dehydratase [30]
IPI00024689 2.61 Aquaporin-CHIP (Aquaporin-1, AQP-1, AQP1) [36]
IPI00027462 3.38 Calgranulin B (S100A9) [37]
IPI00233820 2.61 Catalase* [54,55]
IPI00027438 1.89 Flotillin-1 [38]
IPI00328602 123.42 heat shock 90 kDa protein 1, alpha [33,56]
IPI00217966 634.23 L-lactate dehydrogenase A* [39]
IPI00298860 2.88 Lactotransferrin precursor (Lactoferrin)
[Contains: Lactoferroxin A
[40]
IPI00218342 31.93 Methylenetetrahydrofolate dehydrogenase 1
(MTHFD1)
[41]
IPI00022434 2.08 Serum albumin precursor [43]
IPI00180818 0.18 Aldolase A* [44]
IPI00026119 0.19 Ubiquitin-activating enzyme E1* [45]
N.B. Proteins shown in bold letters have been reported by Pasini et. al. [8] to be present in RBC membrane and those with asterisks have been reported by
Goodman et. al. [7] to be present in whole RBC proteome.
Figure 3 V a l i d a t i o no fi n c r e a s ei nH S P 9 0p r o t e i ni nR B C
membrane proteome of AD subjects. (A) Western blot analysis of
HSP90 and beta-actin protein in RBC membrane samples from
pooled control (C) and five AD subjects (A1-A5). (B) After
normalization of actin band intensities in AD samples (A1-A5) with
respect to actin band in control sample, ratios of HSP90 band
intensities in AD vs. control show elevation of HSP90 in four AD
subjects (A1, A2, A4 and A5). The positive control band of HSP90 is
shown next to A5 (heavy band).
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This investigation of RBC membrane proteome changes
in AD subjects was a pilot study of 10 subjects (5 AD
subjects and 5 controls) as part of a National Institute on
Aging (NIA) approved study “Immune and Other Bio-
Markers of Alzheimer’s Disease” (NIA protocol # 2005-
095), which was included in the Wake Forest University
School of Medicine Ginkgo Evaluation of Memory Study
[46] (GEMS), as reported earlier [1]. Briefly, each AD
case was identified based on their scores on a preliminary
battery of 3 tests (3MSE, Modified Mini-Mental State
Examination (scale 1 to 100) [47], CDR, Clinical Demen-
tia Rating [48] and ADAS, Alzheimer’s Disease Assess-
ment Scale [49]) followed by a full neuropsychological
battery (NPB), a standardized examination by a neurolo-
gist and a brain magnetic resonance imaging (MRI) scan.
All these data were then used by a panel with expertise in
dementia diagnosis to confirm dementia incidence and
classify according to dementia subtype. This procedure
made it possible to diagnose subjects in the early stage of
AD. Thus, all AD subjects were at an early stage of AD
with very mild dementia (a CDR of 0.5 and 3MSE score
as low as 70). Control cases were matched for age and
cardiovascular disease history with 3MSE score of 90 or
above. None of the subjects reported any incidence of
disease that required hospitalization including cardiovas-
cular disease such as angina, Congestive heart failure
(CHF), stroke/Transient ischemic attack (TIA) or Periph-
eral vascular disease (PVD) during 6 months prior to
sample collection. Characteristics of all participants in
our RBC proteome study as regards their age, gender,
medications used are listed in Table 3.
Blood samples from five AD subjects and five age-
matched controls were collected in heparinised (green cap)
tubes at Roena Kulynych Center, Wake Forest University
School of Medicine (Winston-Salem, North Carolina).
Blood was centrifuged at low speed (~1125 × g) to remove
plasma. The pelleted cells were washed three times (each
time a portion of top layer of RBC removed to minimize
contamination of nucleated cells) with phosphate buffered
saline (PBS) containing 100 μM disodium EDTA. Washed
red blood cells (pellets) were shipped frozen on dry ice to
our NIA laboratory at Baltimore for further processing.
Samples upon receipt were stored at -150°C.
Isolation of membrane proteins
Membrane proteins were isolated from RBC pellets
shipped overnight in dry ice and stored frozen at -150°C.
Frozen RBC pellets were thawed in the presence of 1 mM
(final conc.) phenyl methyl sulfonyl fluoride (PMSF) a ser-
ine protease inhibitor by adding a stock solution of 100
mM PMSF in ethanol to the cell pellet. PMSF is well
documented as an irreversible serine protease inhibitor in
the pH range of 4 to 8.5 [50,51] and has been used in pro-
teomic studies [52]. After thawing, 100 μla l i q u o t so ft h e
cell pellet from each of the 5 control samples and from
each of the five Alzheimer’s samples were pooled sepa-
rately resulting in a final volume of 500 μl for each cate-
gory. In order to take into account potential variability in
membrane protein solubilization, three different condi-
tions (Runs 1-3) were used to prepare membranes and
solubilize them. Cells in the pool of RBC pellets were
lysed by diluting them by the addition of 9 ml of 10 mM
Phosphate buffer, pH 7.4 (Runs 1 and 3) or 9 ml of 5 mM
Phosphate buffer, pH 8.0 (condition used to prepare white
ghosts [6] (Run 2)). In each buffer, inhibition of proteolysis
was also maintained by the addition of PMSF (1 mM final
conc.). Hemolysates were centrifuged either at ~39,000 ×
g (Runs 1 and 3) or at ~9000 × g [6] (Run 2) for 30 min.
Membrane pellets were resuspended in 10 mM Phosphate
buffer, pH 7.4 (Runs 1 and 3) or 5 mM Phosphate buffer,
pH 8.0 (Run 2) and washed by centrifuging at ~39,000 × g
( R u n s1a n d3 )o ra t~ 2 0 , 0 0 0×g[ 6 ]( R u n2 )u n t i lt h e
supernatant was clear. Membrane pellets were solubilized
by vortexing with 500 μl of either of 10 mM Tris.HCl, pH
7.4 containing 2% SDS (Runs 1 and 2) or SIGMA Protein
Extraction Reagent Type 4(Run 3) containing urea,
Table 3 Personal and medication data of AD (A1-A5) and
control (C1-C5) subjects used in this study
Subject Gender Age Medications taken
A1 Female 81 ESTRGN
A2 Female 84 ACED, NTCA, THRY, HTNMED
A3 Male 89 ASA
A4 Male 99 ADPI, ASA, HCTZ
A5 Male 85 ALZH
C1 Female 83 ASA, BETA, LOOP, DIUR, HTNMED
C2 Female 91 ASA, COX2, THRY
C3 Male 87 ASA, DLTIR, NSAID, CCBIR, CCB, HTNMED
C4 Male 87 HCTZ, PPI, DIUR, HTNMED
C5 Male 85 None
N.B. Medication abbreviations are ACED (Ace inhibitors with diuretics), ADPI
(Inhibitors of ADP-induced platelet aggregation), ALZH (Acetylcholine esterase
inhibitors for AD), ASA (Aspirin), BETA (Beta-blockers without diuretics), CCB
(Any Calcium-channel blocker = CCIR OR CCBSR OR CCBT), CCBIR (Immediate-
release CCBS = NIFIR OR DIHIR OR VERIR OR DLTIR), CCBT (T-type Calcium-
channel blocker), COX2 (COX-2 inhibitors (NSAID Agents); separate from
NSAID variable), DIHIR (Immediate-release Dihydropyridines other than
Nifedipine), DIUR (Any diuretic), DLTIR (Immediate-release Diltiazem), ESTRGN
(Estrogens, excluding vaginal creams), HCTZ (Thiazide diuretics without K-
sparing agents), HTNMED (Any anti-hypertensive medication), LOOP (Loop
diuretics), NIFIR (Immediate-release Nifedipine), NSAID (Non-steroidal anti-
inflammatory agents, excluding Aspirin), NTCA (Non-tricyclic antidepressants
other than MAO Inhibitors), PPI (Proton pump inhibitors), THRY (Thyroid
agents), VERIR (Immediate-release Verapamil),
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removed by spinning at ~39,000 × g (Runs 1 and 3) or at
~14,000 × g [6] (Run 2) for 30 min. Protein assay in the
clear supernatants from runs 1 and 2 were performed
using BCA reagent from Pierce, while protein assay in the
clear supernatant from run 3 was performed using
BIORAD Bradford reagent, since urea and thiourea inter-
fered with the BCA assay.
SDS-PAGE Analysis
Samples with ~50 μg (Runs 1 and 2, two lanes each) or
100 μg (Run 3, one lane each) per lane of RBC mem-
brane proteins from control and Alzheimer’ss u b j e c t s
were subjected to SDS-Polyacrylamide gel electrophor-
esis (SDS-PAGE) under reducing conditions on com-
mercial small gradient (NOVEX, 4-20%) gels (Runs 1
and 2) or on regular size gradient gel (Jules Inc., 4-20%)
(Run 3). Following electrophoresis, gels were stained
with coomassie blue. Then each gel was carefully laid
on a glass plate and horizontal slices were cut with new
razor blades for each sample. Each slice was cut into ~1
mm cubes and the pieces were transferred to the corre-
sponding labelled-microfuge tube.
Tryptic digestion
Gel pieces were destained with 25% acetonitrile in
25 mM ammonium bicarbonate (three times), and were
dehydrated with 400 μl of 100% acetonitrile followed by
vacuum drying. Proteins in the gel pieces were then sub-
jected to reductive alkylation by adding 10 mM DTT in
5 mM ammonium bicarbonate, incubating the tubes at
55°C for 45 min, subsequently aspirating the liquid, and
incubating the gel pieces with 150 μlo f5 5m Mi o d o a c e -
tamide in the same buffer in the dark. Residual DTT and
iodoacetamide were washed off the gel pieces with 5 mM
ammonium bicarbonate (four times) and dehydrated for
10 min by the addition of 400 μl of 100% acetonitrile.
Proteins in gel pieces were then digested overnight with
Trypsin Gold, (Mass Spectrometry Grade) from Promega
(trypsin: protein was about 1:20) at 37°C to obtain the
corresponding peptides. The peptides were then eluted
from gel pieces with 50% Acetonitrile, 45% HPLC grade
water, and 0.5% formic acid (two times) and once with
100% acetonitrile. The eluted fractions were pooled,
dried in a SpeedVac (Savant ThermoFisher), and dis-
solved in 10 μl of sample buffer (5% acetonitrile, 0.1%
formic acid, 97.9% HPLC grade water).
LC-MS-MS
Samples (10 μl) were injected by an auto-injector (CTC-
Autosampler, CTC Analytics) with a flow rate of
500 nl/min into a LTQ linear ion trap mass spectrometer
(ThermoElectron) for LC-MS-MS analysis as described by
Johanssen et. al. [53]. During LC, a linear gradient from
95% mobile phase A (2% acetonitrile, 0.1% formic
acid, 97.9% HPLC grade water) to 90% mobile phase B
(2% HPLC grade water, 0.1% formic acid, 97.9% acetoni-
trile) was used for 110 min followed by 95% mobile phase
A for 10 min. The peptides were detected in positive ion
mode in the mass spectrometer using a data-dependent
method in which the seven most abundant ions detected
in an initial survey scan were selected for MS-MS analysis.
Each scan cycle consisted of one full scan mass spectrum
(m/z 400-1800) collected in profile mode followed by six
MS-MS events in centroid mode.
Peptide Database Search
Raw MS-MS data were analyzed by Spectrum Mill pro-
teomics software (Rev A03.02.060, Agilent Technologies,
Santa Clara, CA) after extracting them under default
conditions. The extracted files were searched against the
human non-redundant International Protein Index (IPI)
human sequence database http://www.ebi.ac.uk using
trypsin as the protease allowing for a maximum of three
missed cleavages, including fixed modification of carba-
midomethylation and variable modifications of oxidized
methionine and N-terminal glutamine conversion to
pyroglutamic acid in the search. Only proteins with at
least two validated peptides and a total score 25 or
more were considered valid for reporting. To compare
identified proteins between AD and normal groups, the
number of spectra and the summed ion intensity of pep-
tides for each protein (total ion intensity) were used as
indicators of protein amounts. Because these were semi
quantitative metrics, we added total intensities for each
protein in all three runs for AD and normal subjects
separately - then divided them to calculate ratio AD/
normal determining if the protein level was elevated
(greater than or equal to 1.5) or reduced (less than or
equal to 0.67) in AD subjects. Cellular locations of the
proteins were determined by using ProteinCenter pro-
gram version 2.01 (PROXEON, Denmark).
Western blot analysis
Western blot analysis of HSP90 along with cell standard
beta-actin protein was performed on RBC membrane
proteins isolated from pooled samples of control sub-
jects and individual samples of five AD subjects pre-
pared as described above. Proteins (50 μg per lane) were
separated by SDS-PAGE on NOVEX 4-12% Tris-glycine
gels, blotted to PVDF membranes, and probed for
HSP90 and beta-actin by using a mouse monoclonal
anti-HSP90 (BD Biosciences) and a rabbit polyclonal
anti-actin (Santa Cruz Biotechnology) antibody (both at
1:1000 dilution) and WesternBreeze Chemiluminescent
Kits (anti-mouse and anti-rabbit) from Invitrogen
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Page 7 of 9respectively. Band intensities of HSP-90 and actin bands
in the western blot were quantitated upon scanning the
blot and measuring the band pixel volume by Image-
Quant TL software (GE Healthcare).
Additional file 1: List of 160 proteins in RBC proteome with their
levels altered (Fold change) in AD subjects in comparison to their
matched controls (AD/Normal) along with their IPI accession
numbers, and linked gene names.
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